|1.||Nishiyama, Yasuhiro: 5 articles (03/2012 - 12/2005)|
|2.||Paul, Sudhir: 5 articles (03/2012 - 12/2005)|
|3.||Lacroix-Desmazes, Sébastien: 4 articles (04/2005 - 11/2002)|
|4.||Nevinsky, G A: 4 articles (06/2004 - 03/2001)|
|5.||Planque, Stephanie: 3 articles (03/2012 - 05/2008)|
|6.||Buneva, Valentina N: 3 articles (07/2005 - 05/2002)|
|7.||Kazatchkine, Michel D: 3 articles (03/2005 - 11/2002)|
|8.||Buneva, V N: 3 articles (06/2004 - 03/2001)|
|9.||Hifumi, Emi: 2 articles (09/2011 - 01/2008)|
|10.||Uda, Taizo: 2 articles (09/2011 - 01/2008)|
03/24/2009 - "Although initially perceived as potentially deleterious, catalytic antibodies have been proposed to participate in the removal of metabolic wastes and in protection against infection. "
04/01/2005 - "Although initially perceived as potentially harmful, catalytic antibodies have been proposed as participants in the removal of metabolic wastes and protection against infection. "
03/15/2005 - "Although initially perceived as potentially deleterious, catalytic antibodies have been proposed to participate in removal of metabolic wastes and protection against infection. "
03/23/2012 - "Constitutive production of catalytic antibodies to a Staphylococcus aureus virulence factor and effect of infection."
09/28/2011 - "This characteristic monoclonal catalytic antibody heavy chain could suppress the infection of the influenza virus in vitro assays."
|2.||Autoimmune Diseases (Autoimmune Disease)
12/01/2005 - "Catalytic antibodies (CAbs) occur naturally in healthy individuals where they may form part of the innate immune system, but are preferentially found in those with autoimmune disease. "
07/18/2005 - "Various catalytic antibodies or abzymes (Abzs) have been detected recently in the sera of patients and animals with many autoimmune diseases, where their presence is most probably associated with autoimmunization. "
01/01/2012 - "Growing evidence suggests important functional roles for catalytic antibodies in homeostasis, autoimmune disease and protection against infection. "
08/01/1997 - "Characterization of thyroglobulin-directed and polyreactive catalytic antibodies in autoimmune disease."
06/01/1996 - "There is an increased production of antigen-specific catalytic antibodies in autoimmune disease. "
06/01/1993 - "The approach in this study demonstrates the use of catalytic antibody technology in medicine and may be applicable to drugs with undesirable effects, particularly in the field of cancer therapy."
12/01/2001 - "The specific activities of these catalytic antibodies varied in the range from 1.83 up to 3.33 kat/kg, which is about one order of magnitude higher than that for IgGs from the sera of cancer patients. "
12/01/1990 - "We also review recent reports in which investigators have used anti-catalytic antibodies and/or gene transfection to demonstrate that uPA is directly involved in tumor cell invasion and metastasis."
11/01/2002 - "Prodrug activation by catalytic antibodies (abzymes) conjugated with anti-tumor antibodies, called antibody-directed abzyme prodrug therapy (ADAPT), has been proposed as a strategy for site-specific drug delivery systems for anti-tumor drugs. "
09/01/2002 - "Synthesis and characterization of a catalytic antibody-HPMA copolymer-Conjugate as a tool for tumor selective prodrug activation."
|4.||Hemophilia A (Haemophilia)
11/01/2002 - "We have recently shown that the catalytic antibodies are highly prevalent among hemophilia A patients with FVIII inhibitors. "
03/01/2013 - "Hydrolysis of factor VIII mediated by catalytic antibodies occurs in haemophilia A patients with or without factor VIII inhibitors."
06/01/2003 - "Catalytic antibodies to factor VIII in haemophilia A."
|5.||Alzheimer Disease (Alzheimer's Disease)
05/01/2008 - "Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease."
04/01/2010 - "We review attempts to treat Alzheimer disease with antibodies that bind amyloid beta peptide (Abeta) and the feasibility of developing catalytic antibodies for this purpose. "
04/01/2013 - "These questions were discussed in sections covering modified Igs with modified efficacy including catalytic antibodies, the role of Fc receptors and complement inducing autoimmune mediated damage, Ig therapy beyond IgG in particular taking a look at the role of IgA and the therapeutic consequences of the different etiologies of excess amyloid beta in Alzheimer's disease and patients with Downs' syndrome. "
|2.||DNA (Deoxyribonucleic Acid)
|3.||Cocaine (Cocaine HCl)
|7.||Immunoglobulin G (IgG)
|8.||Factor VIII (Coagulation Factor VIII)